Suven Life Sciences gains on patent rights
[2008-4-1]
Meanwhile, the BSE Sensex was down 467.51 points, or 2.86%, to 15,903.78 on negative cues from the global markets. US stocks fell on Friday, 28 March 2008, as a profit warning from US department store chain J.C. Penney raised concerns about slowing consumer spending while persistent worries about credit-related problems throttled financial stocks. A prominent analyst warned that earnings would not support current dividend payouts in 2008 at Citigroup, Wachovia Corp and other US banks.
On BSE, 55,787 shares were traded in the counter. The scrip had an average daily volume of 3.24 lakh shares in the past one quarter.
The stock hit a high of Rs 34.50 and a low of Rs 32.05 so far during the day. The stock had a 52-week high of Rs 64.45 on 28 December 2007 and a 52-week low of Rs 28 on 19 October 2007.
The small-cap scrip had outperformed the market over the past one month till 28 March 2008, declining 7.81% compared to the Sensex’s fall of 8.15%. It had underperformed the market in the past one quarter, declining 46.08% compared to Sensex’s decline of 18.98%.
The company’s current equity is Rs 11.57 crore. Face value per share is Rs 1.
The current price of Rs 33.60 discounts its Q3 December 2007 annualized EPS of Rs 0.70, by a PE multiple of 48.
The patents are valid till 2023.
Suven Life Sciences net profit declined 47.5% to Rs 2.01 crore on 12% fall in net sales to Rs 27.46 crore in Q3 December 2007 over Q3 December 2006.
Suven Life Sciences’ principal activity is to design, manufacture and the supply of bulk active, drug intermediates and fine chemicals to the life science industry. The company mainly operates in the USA, Europe, Asia and India.
On BSE, 55,787 shares were traded in the counter. The scrip had an average daily volume of 3.24 lakh shares in the past one quarter.
The stock hit a high of Rs 34.50 and a low of Rs 32.05 so far during the day. The stock had a 52-week high of Rs 64.45 on 28 December 2007 and a 52-week low of Rs 28 on 19 October 2007.
The small-cap scrip had outperformed the market over the past one month till 28 March 2008, declining 7.81% compared to the Sensex’s fall of 8.15%. It had underperformed the market in the past one quarter, declining 46.08% compared to Sensex’s decline of 18.98%.
The company’s current equity is Rs 11.57 crore. Face value per share is Rs 1.
The current price of Rs 33.60 discounts its Q3 December 2007 annualized EPS of Rs 0.70, by a PE multiple of 48.
The patents are valid till 2023.
Suven Life Sciences net profit declined 47.5% to Rs 2.01 crore on 12% fall in net sales to Rs 27.46 crore in Q3 December 2007 over Q3 December 2006.
Suven Life Sciences’ principal activity is to design, manufacture and the supply of bulk active, drug intermediates and fine chemicals to the life science industry. The company mainly operates in the USA, Europe, Asia and India.
Related News »
In Focus »
footwear exports
Last month, European footwear manufacturers proposed extending anti-dumping measures against ..
B2B Keywords:
International market Chinese Importer Wholesale trade Wholesale products World trade Wholesale distributors International trade Foreign trade Wholesale distributor Importers Import export business Sell online Help u sell Global trade How to market a product Online supplier Wholesale product
International market Chinese Importer Wholesale trade Wholesale products World trade Wholesale distributors International trade Foreign trade Wholesale distributor Importers Import export business Sell online Help u sell Global trade How to market a product Online supplier Wholesale product
Feature Products»
Hot Products: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0-9
-
-
About Us -
Links -
Privacy Policy -
Terms of Use -
Site Map -
Contact Us -
Call Center: 0086-95105561 © 2007 Tootoo.com -
